These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19442620)

  • 1. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
    Hirbe AC; Roelofs AJ; Floyd DH; Deng H; Becker SN; Lanigan LG; Apicelli AJ; Xu Z; Prior JL; Eagleton MC; Piwnica-Worms D; Rogers MJ; Weilbaecher K
    Bone; 2009 May; 44(5):908-16. PubMed ID: 19442620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
    Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
    J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
    Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
    Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
    Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
    Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
    Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells.
    Das S; Edwards PA; Crockett JC; Rogers MJ
    Biochim Biophys Acta; 2014 Apr; 1841(4):569-73. PubMed ID: 24369118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
    Mundy GR; Yoneda T; Hiraga T
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
    Guenther A; Gordon S; Tiemann M; Burger R; Bakker F; Green JR; Baum W; Roelofs AJ; Rogers MJ; Gramatzki M
    Int J Cancer; 2010 Jan; 126(1):239-46. PubMed ID: 19621390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
    Li X; Liao J; Park SI; Koh AJ; Sadler WD; Pienta KJ; Rosol TJ; McCauley LK
    Bone; 2011 Jun; 48(6):1354-61. PubMed ID: 21419883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Green JR; Guenther A
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of bisphosphonates.
    Green JR
    Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
    Odri G; Kim PP; Lamoureux F; Charrier C; Battaglia S; Amiaud J; Heymann D; Gouin F; Redini F
    BMC Cancer; 2014 Mar; 14():169. PubMed ID: 24612486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.
    Räikkönen J; Crockett JC; Rogers MJ; Mönkkönen H; Auriola S; Mönkkönen J
    Br J Pharmacol; 2009 Jun; 157(3):427-35. PubMed ID: 19371349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
    Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
    Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
    Pozzi S; Vallet S; Mukherjee S; Cirstea D; Vaghela N; Santo L; Rosen E; Ikeda H; Okawa Y; Kiziltepe T; Schoonmaker J; Xie W; Hideshima T; Weller E; Bouxsein ML; Munshi NC; Anderson KC; Raje N
    Clin Cancer Res; 2009 Sep; 15(18):5829-39. PubMed ID: 19737962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.
    Kuroshima S; Go VA; Yamashita J
    Endocrinology; 2012 Jan; 153(1):17-28. PubMed ID: 22109892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates: preclinical review.
    Green JR
    Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone.
    Li M; Wang W; Zhu Y; Lu Y; Wan P; Yang K; Zhang Y; Mao C
    Acta Biomater; 2018 Sep; 77():365-379. PubMed ID: 30030174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.